|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2007-3-28
|
|
pubmed:abstractText |
The purpose of the study was to evaluate the effects of erlotinib on epidermal growth factor receptor (EGFR)-related signaling elements in tumor and skin from patients with advanced squamous cell carcinoma of the head and neck (HNSCC) and seek relationships between relevant clinical, biological, and pharmacokinetic parameters.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
18
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
761-7
|
|
pubmed:dateRevised |
2009-11-19
|
|
pubmed:meshHeading |
pubmed-meshheading:17317676-Adolescent,
pubmed-meshheading:17317676-Adult,
pubmed-meshheading:17317676-Aged,
pubmed-meshheading:17317676-Aged, 80 and over,
pubmed-meshheading:17317676-Carcinoma, Squamous Cell,
pubmed-meshheading:17317676-Cyclin-Dependent Kinase Inhibitor p27,
pubmed-meshheading:17317676-Extracellular Signal-Regulated MAP Kinases,
pubmed-meshheading:17317676-Female,
pubmed-meshheading:17317676-Head and Neck Neoplasms,
pubmed-meshheading:17317676-Humans,
pubmed-meshheading:17317676-Immunohistochemistry,
pubmed-meshheading:17317676-Male,
pubmed-meshheading:17317676-Middle Aged,
pubmed-meshheading:17317676-Quinazolines,
pubmed-meshheading:17317676-Receptor, Epidermal Growth Factor,
pubmed-meshheading:17317676-Skin
|
|
pubmed:year |
2007
|
|
pubmed:articleTitle |
Assessment of erlotinib pharmacodynamics in tumors and skin of patients with head and neck cancer.
|
|
pubmed:affiliation |
Cancer Therapy and Research Center, The Institute for Drug Development, San Antonio, TX, USA.
|
|
pubmed:publicationType |
Journal Article
|
